NZ774327A - Therapeutic antibodies and their uses - Google Patents

Therapeutic antibodies and their uses

Info

Publication number
NZ774327A
NZ774327A NZ774327A NZ77432716A NZ774327A NZ 774327 A NZ774327 A NZ 774327A NZ 774327 A NZ774327 A NZ 774327A NZ 77432716 A NZ77432716 A NZ 77432716A NZ 774327 A NZ774327 A NZ 774327A
Authority
NZ
New Zealand
Prior art keywords
seq
sequence shown
antibody
cdr1
cdr2
Prior art date
Application number
NZ774327A
Other versions
NZ774327B2 (en
Inventor
Arvind Rajpal
Blarcom Thomas Van
Tracy Chia-Chien Kuo
Riggers Javier Fernando Chaparro
Wei Chen
Amy Shaw-Ru Chen
Edward Derrick Pascua
Leila Marie Boustany
Yik Andy Yeung
Pavel Strop
Weihsien Ho
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55661497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ774327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Priority claimed from NZ735052A external-priority patent/NZ735052B2/en
Publication of NZ774327A publication Critical patent/NZ774327A/en
Publication of NZ774327B2 publication Critical patent/NZ774327B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to an antibody, e.g., full length antibody or antigen binding fragments thereof, that specifically bind to CD3 (Cluster of Differentiation 3). The invention also relates to pharmaceutical compositions comprising the said CD3 antibody, and methods for producing the same.

Claims (12)

Claims It is claimed:
1. 5 10 15 20 25 30 An isolated antibody, or an antigen binding fragment thereof, which specifically binds to CD3, wherein the antibody comprises (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 331, 332 or 333 (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 336 or 417; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 335; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 343; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 341; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 342.
2. The antibody or antigen binding fragrment of claim 1, wherein the antibody comprises: a) (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 332 (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 417; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 335; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 343; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 341; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 342; b) (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 331 (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 336; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 335; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 343; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 341; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 342; or c) (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 333 (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 336; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 335; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 343; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 341; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 342.
3. The antibody or antigen binding fragment of claim 1 or 2, wherein the antibody comprises a VH comprising the sequence shown in SEQ ID NO: 324.
4. 5 10 15 20 25 The antibody or antigen binding fragment of any one of claims 1 to 3, wherein the antibody comprises a VL comprising the sequence shown in SEQ ID NO: 323.
5. The antibody or antigen binding fragment of any one of claims 1 to 4, wherein the antibody comprises a VH comprising the sequence shown in SEQ ID NO: 324 and a VL comprising the sequence shown in SEQ ID NO: 323.
6. An isolated antibody, or an antigen binding fragment thereof, which specifically binds to CD3, wherein the antibody comprises a VH produced by the expression vector with ATCC Accession No. PTA-122513 and a VL produced by the expression vector with ATCC Accession No. PTA-122512.
7. claims 1 to 6.
8. A pharmaceutical composition comprising the antibody of any one of An isolated polynucleotide comprising a nucleotide sequence encoding the antibody of any one of claims 1 to 6.
9.
10. A vector comprising the polynucleotide of claim 8. An isolated host cell that recombinantly produces the antibody or the antigen binding fragment of any one of claims 1 to 6, provided that if the cell is a human cell it is ex vivo.
11. A method of producing an antibody, comprising culturing the host cell of claim 10 under conditions that result in production of the antibody, and isolating the antibody from the host cell or culture.
12. The antibody or antigen binding fragment of claim 1 or 6, substantially as herein described with reference to any one of the examples and/or
NZ774327A 2016-03-30 Therapeutic antibodies and their uses NZ774327B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562146843P 2015-04-13 2015-04-13
US201562146504P 2015-04-13 2015-04-13
US201662301582P 2016-02-29 2016-02-29
NZ735052A NZ735052B2 (en) 2016-03-30 Therapeutic antibodies and their uses

Publications (2)

Publication Number Publication Date
NZ774327A true NZ774327A (en) 2025-03-28
NZ774327B2 NZ774327B2 (en) 2025-07-01

Family

ID=

Also Published As

Publication number Publication date
SA517390140B1 (en) 2021-11-24
AU2022203601B2 (en) 2025-07-10
PE20221262A1 (en) 2022-08-16
AU2016248946C1 (en) 2024-10-17
PH12023550222A1 (en) 2024-03-11
SG10201912819XA (en) 2020-02-27
IL254219A0 (en) 2017-10-31
HUS2400014I1 (en) 2024-06-28
PL3988117T3 (en) 2025-03-10
US11814435B2 (en) 2023-11-14
PT3988117T (en) 2025-01-23
KR20200053642A (en) 2020-05-18
NO2025024I1 (en) 2025-05-26
NO2026008I1 (en) 2026-02-19
FI4234581T3 (en) 2025-11-24
JP6913025B2 (en) 2021-08-04
ES3012402T3 (en) 2025-04-09
EP3283106B1 (en) 2021-12-22
CN114773476A (en) 2022-07-22
EP4234581B1 (en) 2025-09-17
CA3219680A1 (en) 2016-10-13
CN119708245A (en) 2025-03-28
HUE069499T2 (en) 2025-03-28
AU2016248946A1 (en) 2017-09-21
AU2022203620A1 (en) 2022-06-16
PL4234581T3 (en) 2026-01-26
HUS2500022I1 (en) 2025-06-28
EP3988117A1 (en) 2022-04-27
US20180171018A1 (en) 2018-06-21
IL310723A (en) 2024-04-01
FR26C1010I1 (en) 2026-04-17
NZ735052A (en) 2025-03-28
CA2925329C (en) 2024-01-02
IL290496A (en) 2022-04-01
HUE057285T2 (en) 2022-04-28
NL301271I2 (en) 2026-02-17
FR24C1023I1 (en) 2024-07-26
PE20180046A1 (en) 2018-01-15
MX2022001830A (en) 2022-03-17
FR24C1023I2 (en) 2026-04-03
EP3988117B1 (en) 2024-11-27
HUE073610T2 (en) 2026-01-28
KR102110557B1 (en) 2020-05-15
MX2022001831A (en) 2022-03-17
CA3219665A1 (en) 2016-10-13
EP4647446A3 (en) 2026-02-18
CA3219684A1 (en) 2016-10-13
WO2016166629A1 (en) 2016-10-20
SG11201707192XA (en) 2017-10-30
CN108136002A (en) 2018-06-08
BR112017019785B1 (en) 2022-11-16
ES3053863T3 (en) 2026-01-27
JP2021169486A (en) 2021-10-28
RU2017133826A3 (en) 2019-05-13
HRP20251284T1 (en) 2025-12-05
KR20200053641A (en) 2020-05-18
FI3988117T3 (en) 2025-01-27
PH12017501732A1 (en) 2018-04-02
US20180298108A1 (en) 2018-10-18
JP2023109898A (en) 2023-08-08
BR112017019785A2 (en) 2018-05-22
IL254219B (en) 2022-03-01
SG10201912823PA (en) 2020-02-27
TWI703157B (en) 2020-09-01
MY196625A (en) 2023-04-23
FIC20260009I1 (en) 2026-03-05
TWI787645B (en) 2022-12-21
AU2025248718A1 (en) 2025-10-30
PL3283106T3 (en) 2022-05-02
KR102405104B1 (en) 2022-06-07
LUC00344I1 (en) 2024-05-22
TW201706311A (en) 2017-02-16
CN114874331A (en) 2022-08-09
JP2018516068A (en) 2018-06-21
CO2017010495A2 (en) 2018-01-05
IL290488B1 (en) 2024-03-01
HK1255385A1 (en) 2019-08-16
ES2905315T3 (en) 2022-04-07
CN108136002B (en) 2022-05-31
US11155630B2 (en) 2021-10-26
CA2925329A1 (en) 2016-10-13
JP2025081581A (en) 2025-05-27
ZA201807153B (en) 2022-08-31
KR102405099B1 (en) 2022-06-07
SI4234581T1 (en) 2026-01-30
SI3988117T1 (en) 2025-03-31
US10793635B2 (en) 2020-10-06
JP2025081580A (en) 2025-05-27
EP4234581A3 (en) 2023-10-04
DK4234581T3 (en) 2025-10-06
RU2017133826A (en) 2019-05-13
US20210054087A1 (en) 2021-02-25
US20240018252A1 (en) 2024-01-18
FIC20250021I1 (en) 2025-05-27
PT3283106T (en) 2022-02-02
AU2016248946B2 (en) 2022-03-10
FIC20240014I1 (en) 2024-05-21
PT4234581T (en) 2025-11-18
TWI703159B (en) 2020-09-01
EP4647446A2 (en) 2025-11-12
US20160297885A1 (en) 2016-10-13
EP4234581A2 (en) 2023-08-30
LUC00344I2 (en) 2026-05-05
AU2022203620B2 (en) 2025-07-10
US9969809B2 (en) 2018-05-15
US10040860B2 (en) 2018-08-07
JP7641323B2 (en) 2025-03-06
DK3988117T3 (en) 2025-01-20
KR20170131699A (en) 2017-11-29
TW201811833A (en) 2018-04-01
IL310723B1 (en) 2026-07-01
EP3283106A1 (en) 2018-02-21
SI3283106T1 (en) 2022-04-29
NZ774326A (en) 2025-03-28
PE20221580A1 (en) 2022-10-06
FR25C1020I1 (en) 2025-08-01
IL290488B2 (en) 2024-07-01
HRP20241757T1 (en) 2025-02-28
IL290488A (en) 2022-04-01
TW202115120A (en) 2021-04-16
US20210188991A1 (en) 2021-06-24
MX2017013297A (en) 2018-06-19
DK3283106T3 (en) 2022-01-10
AU2022203601A1 (en) 2022-06-16
CN114874331B (en) 2025-01-07
RU2722381C2 (en) 2020-05-29
PH12023550223A1 (en) 2024-03-11
CN114773476B (en) 2025-09-09

Similar Documents

Publication Publication Date Title
PE20240218A1 (en) AFFINITY MATURED AND HUMANIZED ANTIBODIES TO FCRH5
MY198034A (en) Tumor-targeted agonistic cd28 antigen binding molecules
PE20200862A1 (en) ANTI-TREM2 ANTIBODIES AND RELATED METHODS
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PE20221262A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
WO2018170351A8 (en) Anti-phf-tau antibodies and uses thereof
PE20181952A1 (en) ANTI-LL-33 ANTIBODIES, COMPOSITIONS, METHODS AND USES OF THE SAME
NZ610734A (en) Human antibodies to the glucagon receptor
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
JP2013520984A5 (en)
RU2014103784A (en) ANTIBODY LOCKING AGR2 AND ITS APPLICATION
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
WO2020218951A3 (en) Monoclonal antibody that binds specifically to gitr
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
FI3515947T3 (en) Novel antibodies against factor xi and uses thereof
NZ774327B2 (en) Therapeutic antibodies and their uses
EA202092672A1 (en) ANTIBODIES AGAINST DLL3 AND THEIR APPLICATION
LT2010104A (en) Single stranded recombinant antibody fragment able to neutralize cytolytic activity of vaginolysin
HK20008640A1 (en) Monoclonal antibody that specifically binds to gitr
NZ779866A (en) Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2027 BY THOMSON REUTERS

Effective date: 20260202